The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Study of the usefulness of angiotensin type 1 receptor (AGTR1) as a possible response predictor in patients with metastatic breast cancer (mBC) subjected to chemotherapy and treatment with bevacizumab (AVALUZ Study).
Juan De la Haba- Rodriguez
No relevant relationships to disclose
Javier Salvador Bofill
No relevant relationships to disclose
Manuel Codes
No relevant relationships to disclose
Eva M. Ciruelos
No relevant relationships to disclose
Ana Jaen
No relevant relationships to disclose
Antonio Galan
No relevant relationships to disclose
Miquel Gil
No relevant relationships to disclose
M. Jose Serrano
No relevant relationships to disclose
Jose Manuel Baena
No relevant relationships to disclose
Maria Jose Villanueva Silva
No relevant relationships to disclose
Encarnacion Gonzalez
No relevant relationships to disclose
Adolfo Murias
No relevant relationships to disclose
Ana Miguel
No relevant relationships to disclose
Helena Garcia
No relevant relationships to disclose
Juan L. Bayo
No relevant relationships to disclose
Pedro Sánchez-Rovira
No relevant relationships to disclose